Childhood cancers are relatively rare diseases, but they cause a serious threat to a child’s life. Patients and their family members, together with medical care professionals involved in the treatment of Childhood cancers, constantly hope for new treatment options to become available for use.
In order to meet this unmet medical need, Ohara Pharmaceutical Co., Ltd. will continue to proactively engage in research and development activities in order to identify and make available for use new treatment options.
While relatively rare, there are more than 50 types of childhood cancers. In Japan, the most common type is leukemia, followed by brain tumors, Neuroblastoma, and malignant lymphoma.